BridgeBio CEO sells 28,053 shares under 10b5-1 plan

BridgeBio Pharma, Inc. Chief Executive Officer Neil Kumar reported open-market sales of a total of 28,053 shares of common stock on February 19, 2026.

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. Chief Executive Officer Neil Kumar reported open-market sales of a total of 28,053 shares of common stock on February 19, 2026. The sales were executed in three tranches of 18,923, 8,528 and 602 shares at weighted average prices of $71.0347, $72.0804 and $72.8010 per share, respectively, pursuant to a pre-arranged Rule 10b5-1 sales plan adopted on March 31, 2025.

Following these transactions, Kumar directly owned 234,451 shares of BridgeBio common stock. He also had indirect ownership of 675,686 shares through the Kumar Haldea Family Irrevocable Trust and 4,478,447 shares through the Kumar Haldea Revocable Trust, as co-trustee, while disclaiming beneficial ownership except to the extent of any pecuniary interest.

Insider Trade Summary

Net Seller: 28,053 shares

Net Sell 5 txns

Insider Kumar Neil

Role Chief Executive Officer

Sold 28,053 shs ($2.00M)

Type	Security	Shares	Price	Value
Sale	Common Stock	18,923	$71.0347	$1.34M
Sale	Common Stock	8,528	$72.0804	$615K
Sale	Common Stock	602	$72.801	$44K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 234,451 shares (Direct); Common Stock — 675,686 shares (Indirect, By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.); Common Stock — 4,478,447 shares (Indirect, By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.)

Footnotes (5)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
2. F2. Represents the weighted average sale price of the shares sold from $70.61 to $71.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
3. F3. Represents the weighted average sale price of the shares sold from $71.61 to $72.57 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
4. F4. Represents the weighted average sale price of the shares sold from $72.61 to $72.86 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
5. F5. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

FAQ

What insider transaction did BridgeBio (BBIO) CEO Neil Kumar report?

Neil Kumar reported open-market sales of BridgeBio common stock. On February 19, 2026, he sold 28,053 shares in three transactions under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2025, according to the Form 4 filing.

How many BridgeBio (BBIO) shares did Neil Kumar sell and at what prices?

Neil Kumar sold 28,053 BridgeBio shares. The sales occurred in three blocks of 18,923, 8,528 and 602 shares at weighted average prices of $71.0347, $72.0804 and $72.8010 per share, within specified intraday price ranges disclosed in the filing footnotes.

How many BridgeBio (BBIO) shares does Neil Kumar own directly after this Form 4?

After the reported sales, Neil Kumar directly owned 234,451 shares of BridgeBio common stock. This figure reflects his direct holdings only and excludes additional shares held indirectly through related trusts listed separately in the Form 4 filing.

What indirect BridgeBio (BBIO) holdings related to Neil Kumar are shown in the Form 4?

The Form 4 lists 675,686 shares held by the Kumar Haldea Family Irrevocable Trust and 4,478,447 shares held by the Kumar Haldea Revocable Trust. Neil Kumar is a co-trustee of both trusts and disclaims beneficial ownership except to the extent of any pecuniary interest.

Was Neil Kumar’s sale of BridgeBio (BBIO) shares under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 sales plan adopted by Neil Kumar on March 31, 2025. Such plans pre-schedule trades, allowing executives to systematically sell shares according to preset instructions.

What do the Form 4 footnotes say about Neil Kumar’s beneficial ownership of BridgeBio (BBIO) shares?

The footnotes state that Neil Kumar disclaims beneficial ownership of the trust-held shares except to the extent of his pecuniary interest. The report should not be considered an admission that these indirectly held shares are beneficially owned for Section 16 or other purposes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Neil

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		S(1)		18,923	D	$71.0347(2)	243,581	D
Common Stock	02/19/2026		S(1)		8,528	D	$72.0804(3)	235,053	D
Common Stock	02/19/2026		S(1)		602	D	$72.801(4)	234,451	D
Common Stock								675,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(5)
Common Stock								4,478,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

2. Represents the weighted average sale price of the shares sold from $70.61 to $71.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

3. Represents the weighted average sale price of the shares sold from $71.61 to $72.57 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

4. Represents the weighted average sale price of the shares sold from $72.61 to $72.86 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

5. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.